EUCTR2010-020742-10-GB进行中（未招募）不适用
Recombinant Human Insulin-like Growth Factor (rhIGF-1) and Growth Hormone (rhGH) Combination Therapy of Pre-Pubertal Children with Idiopathic Growth Hormone Deficiency and Poor Response to First Year of Growth Hormone Therapy: A Phase II, Prospective, Randomized, Open-label, Multi-Centre, Parallel Group Add-On Study Comparing a Flexible rhIGF-1 Dose and Fixed rhGH Dose vs. Fixed rhGHDose Therapy.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Ipsen Pharma
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Treatment with rhGH at a minimum starting dose of 0.025 mg/kg/day (without dose reduction) to a maximum dose of 0.035 mg/kg/day for at least 12 months and a maximum of 18 months based on the diagnosis of IGHD with a pre-treatment GH stimulation test/spontaneous maximum of GH < 10µg/L
- •First year of rhGH treatment resulting in height gain < 0.5 SDS
- •Chronological age from 3 to 9 years inclusive for girls, from 3 to 10 years inclusive for boys
- •Pre-pubertal: Tanner stage 1 (Girls: Tanner B1, Boys: Testis = 3ml)
- •Parent(s)/guardian(s) have provided written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Evidence (more than 20% rhGH injections missed) or suspicion of poor compliance during the first year of rhGH treatment
- •Hypothalamic-pituitary tumours diagnosed or treated prior to screening
- •Evidence of any active malignancy or intracranial tumours
- •Co-morbidity known to affect linear growth including, but not limited to, skeletal dysplasia
- •Chronic illness including but not limited to diabetes, inborn errors of metabolism, osteochondrodystrophy, disorders of genitourinary, cardiopulmonary, gastrointestinal, or central nervous system
- •Any named syndrome known to be associated with short stature but not limited to Prader-Willi syndrome, Russel Silver syndrome, etc.
- •Neurological disease and mental disabilities that may interfere with compliance [Attention Deficit Hyperactivity Disorders (ADHD), autism, Asperger]
- •Ongoing drug treatment known to alter growth, including but not limited to high dose glucocorticoids
- •Multiple hormonal deficiencies except hypothyroidism if corrected and well controlled
- •Abnormal findings at previous fundoscopy or echocardiogram
- •Significant abnormality in clinical screening laboratories, as determined by the Investigator
- •Syndromes that predispose the subject to cancer (e.g. Fanconi syndrome, Bloom syndrome, ataxia telangectasia)
- •Active seizure disorders, defined as one or more seizures per month irrespective of anticonvulsant therapy
- •Known allergy or hypersensitivity to any components of NutropinAq® (somatropin) or Increlex® (mecasermin)
- •Acute critical illness due to complications following open heart or abdominal surgery, multiple accidental traumas or acute respiratory failure
- •Any current or previous exposure to therapeutic spinal irradiation
- •Prior bone marrow transplantation
- •Evidence of clinical malnutrition or growth deficit attributable to emotional deprivation
- •Participation in a clinical trial within the last 12 weeks
- •Any social or medical condition that, in the opinion of the Investigator, would be detrimental to either the subject or the study
研究者
相似试验
进行中（未招募）
不适用
Comparison of efficacy and safety of Nutropin (rhGH) associated with Increlex (rhIGF-1) vs Nutropin (rhGH) alone [COGROW].Pre-Pubertal Children with Idiopathic Growth Hormone Deficiency and with poor response after one year of treatment.MedDRA version: 13.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2010-020742-10-SEIpsen Pharma63
进行中（未招募）
不适用
Comparison of efficacy and safety of Nutropin (rhGH) associated with Increlex (rhIGF-1) vs Nutropin (rhGH) alone [COGROW].Pre-Pubertal Children with Idiopathic Growth Hormone Deficiency and with poor response after one year of treatment.MedDRA version: 13.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2010-020742-10-FIIpsen Pharma63
Enrolling By Invitation
不适用
Expression of insulin-like growth factors as a prognostic factor in solitary fibrous tumorsICD-10-CM Z85.110 Personal history of malignant carcinoid tumor of bronchus and lungDRKS00021109niversitätsklinikum Freiburg Klinik für Thoraxchirurgie100
招募中
不适用
Premaquick Biomarkers versus Transvaginal Ultrasonographically Measured Cervical Length for Pre-Induction Cervical Assessment at Term: A Double Blind Randomized Studypregnancy and deliveryPACTR202001579275333DR CHIGOZIE OKAFOR72
已完成
不适用
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin ResistanceInsulin ResistanceHyperglycemiaNCT00004419Beth Israel Deaconess Medical Center18